Skin cancer after nonmyeloablative hematopoietic cell transplantation

M. Cavalier, J. A. Shmalo, M. Yu, S. D. Billings, R. Abonour, Ronelson P. Nelson

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Squamous cell carcinoma (SCC) is the most common skin cancer in patients receiving immunosuppressive therapy, and is well documented to occur in patients that have undergone either solid organ transplantation or conventional myeloablative bone marrow transplantation. Nonmyeloablative hematopoietic cell transplantation (NMAT) provides transient, intensive immunosuppression, permitting allogeneic engraftment without ablating the marrow. The purpose of this report is to describe six patients that developed SCC (n=3), basal cell carcinoma (n=2), or malignant melanoma (n=2) over a period of 2-26 months following NMAT. All patients had myelodysplasia or acute myelogenous leukemia prior to transplantation. The authors demonstrate for the first time that patients who undergo NMAT are at risk for developing skin cancers and emphasize the need for close surveillance in the post transplantation period.

Original languageEnglish (US)
Pages (from-to)1103-1108
Number of pages6
JournalBone Marrow Transplantation
Issue number12
StatePublished - Jun 2006


  • Immunosuppression
  • Nonmyeloablative transplantation
  • Skin cancer
  • Squamous cell carcinoma
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Skin cancer after nonmyeloablative hematopoietic cell transplantation'. Together they form a unique fingerprint.

Cite this